36062-04-1
36062-04-1 結(jié)構(gòu)式
基本信息
四氫姜黃素
納米四氫姜黃素
四氫-姜黃色素
水溶性四氫姜黃素
生物活性四氫姜黃素
四氫姜黃素(標(biāo)準(zhǔn)品)
納米脂質(zhì)體四氫姜黃素
納米包裹輔酶四氫姜黃素
四氫姜黃素, 來(lái)源于姜黃
Nsc687845
HZIV 81-2
SabiWhite-
Aids110028
Aids-110028
BioaActive THC
NanoActive THC
TetrahydrocucuMin
etrahydrocurcumin
物理化學(xué)性質(zhì)
制備方法
458-37-7
36062-04-1
以(1E,6E)-1,7-雙(4-羥基-3-甲氧基苯基)庚-1,6-二烯-3,5-二酮為起始原料合成四氫姜黃素的一般步驟：將1g鉑-鐵-鎳氫氧化物復(fù)合納米粒子催化劑與100g姜黃素加入裝有300ml乙醇的反應(yīng)燒瓶中，于24℃室溫條件下攪拌反應(yīng)1小時(shí)。反應(yīng)完成后，通過(guò)減壓蒸餾除去溶劑，得到98g淡黃色粘性物質(zhì)。將該物質(zhì)溶解于400ml乙醇中，隨后濃縮至150ml。將濃縮液置于冰箱中靜置結(jié)晶，最終獲得92.9g淡黃色固體產(chǎn)物，收率為92.9%。
參考文獻(xiàn)：
[1] Patent: CN104496779, 2017, B. Location in patent: Paragraph 0014; 0015; 0016; 0017; 0018-0023
[2] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2001, vol. 40, # 6, p. 495 - 497
[3] Bioorganic and Medicinal Chemistry, 2005, vol. 13, # 22, p. 6175 - 6181
[4] Bioscience, biotechnology, and biochemistry, 1995, vol. 59, # 9, p. 1609 - 1612
[5] Biochemical Pharmacology, 1996, vol. 52, # 4, p. 519 - 525
常見(jiàn)問(wèn)題列表
四氫姜黃素為天然的姜黃根提取物中主要的美白活性成分，不僅具有最強(qiáng)的酪氨酸酶抑制活性，還具有極好的化學(xué)穩(wěn)定性，而且外觀為無(wú)味的白色粉末，從而克服了普通姜黃提取物化學(xué)不穩(wěn)定易使皮膚染色的缺陷。普通的姜黃提取物為黃色，化學(xué)穩(wěn)定性差，具有光敏性，在光照下，容易和皮膚發(fā)生化學(xué)反應(yīng)而使皮膚染色。
|
CYP2C9
|
CYP3A4
|
Human Endogenous Metabolite
|
Autophagy
|
Tetrahydrocurcumin (THC) has a number of attractive properties not shared with Curcumin that may make it superior. Tetrahydrocurcumin inhibited lipoxygenase as low as 1 μM. Tetrahydrocurcumin is tested for its ability to inhibit CYP2C9, CYP3A4, CYP1A2 and CYP2D6. Tetrahydrocurcumin yields dose-dependent inhibition of CYP2C9, and to a lesser extent, CYP3A4. Tetrahydrocurcumin exhibits maximum inhibition of CYP2C9 and CYP3A4 at 50 to 100 μM. Tetrahydrocurcumin does not show a consistent dose-response inhibition of CYP1A2 or CYP2D6 over the range of concentrations tested. In some cases, the percent inhibition exceeds 100%. The effect of Tetrahydrocurcumin on cancer cell viability is measured. Sup-T1 cells, T-cell lymphoblastic lymphoma cells, are treated with Tetrahydrocurcumin to determine its ability to induce growth inhibition using an MTS assay, and the corresponding IC50 values are in the mid-to-high micromolar range.
The serum Tetrahydrocurcumin (THC) concentration versus time curve shows that more than one absorption and distribution phase is present. Initially, a rapid absorption phase with an average Tmax of 6.8 μg/mL at 1 h is observed, followed by a short elimination phase. This is followed by two redistributions with two smaller Tetrahydrocurcumin maxima at 6 and 24 h. Both redistribution phases has similar maxima of about 1 μg/mL. The total amount of Tetrahydrocurcumin excrets unchanged in urine was up to 8 μg at 24 h.